Details of the Drug
General Information of Drug (ID: DM7XIH3)
Drug Name |
(E)-N-(4-Phenylthiazol-2-yl) cinnamamide
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
CHEMBL452100; 2-Cinnamamido-4-phenylthiazole; (2E)-3-phenyl-N-(4-phenyl-1,3-thiazol-2-yl)prop-2-enamide; 1107621-03-3; AC1LEPJR; (E)-N-(4-Phenylthiazol-2-yl) cinnamamide; ZINC60264; WOJRHCOBUKJCAJ-VAWYXSNFSA-N; MolPort-019-760-060; MolPort-001-931-977; HMS1397P15; STK173781; BDBM50255301; N-(4-phenylthiazol-2-yl)cinnamamide; AKOS000523355; MCULE-8934603681; BAS 00417267; ST4016450; 3-Phenyl-N-(4-phenyl-thiazol-2-yl)-acrylamide; AG-690/11629440; 3-phenyl-N-(4-phenyl-1,3-thiazol-2-yl)acrylamide; F0298-0058; A0793/0037152
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 306.4 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 4.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||